Evidence-based approaches for gut microbiota modulation in IBS
Professor Carmelo Scarpignato discusses the role of gut microbiota in Irritable Bowel Syndrome (IBS) and the potential for evidence-based therapeutic interventions. The interview explores how dysbiosis contributes to symptom development and the current state of microbiota-targeted treatments.
Why it matters
Understanding the gut-brain axis and microbial health is critical for developing new, effective treatments for chronic digestive conditions like IBS.
Alterations in the composition and function of the gut microbiota are recognized as key contributors to the pathophysiology of IBS. In this interview with Prof. Carmelo Scarpignato, we discuss the knowns and unknowns of gut microbiota in IBS, the four levels of gut microbiota manipulation, and examples of microbiota-targeted approaches available for the clinician.
On behalf of IBS Days 2026 conference , we have interviewed Prof. Carmelo Scarpignato on evidence-based approaches for gut microbiota modulation in IBS. Prof. Carmelo Scarpignato is a clinical pharmacologist and gastroenterologist, teaching at different European Universities. His main scientific interests are pathophysiology and therapy of digestive diseases, microbiota-directed therapies, nutraceuticals, and GI-targeted medical devices.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in